Turning Antibodies into Quality Commodities
Once upon a time, antibodies as a critical factor for protein research have previously been one of the toughest reagents to obtain. From the initial stage, such as expressing and purifying the antigen to immunizing a suitable animal, or generating hybridoma cells as well as the purification of end product, each procedure could take several months to finish. However, during the time, a more prosperous antibody production industry is rapidly turning these molecules into commodities with innovative new technologies.
“Nowadays, antibody production is not as tough as it was. There are numerous companies that would rather be very happy to synthesize your intended peptides, or immunize a mouse, a rat or a rabbit, whatever it is, and soon they will deliver the product,” says Linna Green, the marketing director of Creative Diagnostics, one of such antibody production suppliers. She adds that “To step further, the way we serve researchers, to get custom polyclonal antibody production or rabbit monoclonal antibody production, for example, is a very promising commoditized business under the international setting.”
Commodity antibodies, including monoclonal antibodies, polyclonal antibodies, antibody pairs, recombinant antibodies, nanobodies, blood group antibodies, isotype controls and raw materials, has covered a very extensive research needs, though for some targets and applications, they simply cannot at the time.
The reason for the “cannot” is because the way they are produced—standard laboratory platforms. Fortunately, scientists at CD have developed novel antibody production platforms for these special cases.
Its name is Magic-HybridomaTM Platform, which allows generation of 50-200 mouse hybridoma clones per hybridoma cell fusion on the basis of novel immunization adjuvant—the Magic Mouse Adjuvant. The Magic Mouse Adjuvant equips CD scientists the ability to generate a large number of hybridoma clones in mice even only with a very small amount of immunogen for lot of antigens.
As we all know, it is difficult to obtain highly-specific and highly-sensitive antibodies that recognize the antigen in its native conformation, e.g. antibodies used in diagnostics assays and antibodies intended for therapeutic purposes, unless there are a large number of candidate antibody clones to be screened, even in cases in which the immunogen is well designed to mimic the conformation of the antigen. In particular, to have an antibody of therapeutic potential requires production of hundreds of binding antibodies first; after that, binders with desired biological functions can be further isolated. Therefore, Magic-HybridomaTM Platform represents a revolutionary method to produce a large number of monoclonal antibodies for each target.
With this technique, CD is well capable of turning antibodies into quality commodities. To learn more, please read at http://www.creative-diagnostics.com/Magic-HybridomaTM-Platform.html.
About Creative Diagnostics Antibodies
Creative Diagnostics offers thousands of monoclonal and polyclonal antibodies and conjugates validated for use in a variety of common applications including Western blot, Flow cytometry, IHC, ICC, IF, IP, and more. Besides, it also offers secondary antibodies, bulk production, and custom purification, formulations or conjugations to meet researchers’ needs.
Contact
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-diagnostics.com
Post Your Ad Here
Comments